A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John C. Byrd(University of Cincinnati), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erin Molnar(The Ohio State University), Joseph M. Flynn(The Ohio State University), Tasheda Navarro(Pharmacyclics (United States)), Amy J. Johnson(Ouranos), Kami J. Maddocks(The Ohio State University), Ann M. Lowe(Hôpital Edouard Herriot), Mona Stefanos(The Ohio State University), Eric Hedrick(Florida Hospital Cancer Institute), Leslie A. Andritsos(University of New Mexico), Michael R. Grever(The Ohio State University Wexner Medical Center), Kristie A. Blum(Emory University), Susan Devlin(Pharmacyclics (United States)), Danelle F. James(Pharmacyclics (United States)), Jeffrey A. Jones(The Ohio State University), Nyla A. Heerema(The Ohio State University), Susan M. Geyer(Mayo Clinic in Florida)
Cited by 65
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k